The high frequency of p53 mutation in human cancers indicates the important role of p53 in suppressing tumorigenesis. It is well established that the p53 regulates multiple, distinct cellular functions such as cell-cycle arrest and apoptosis. Despite intensive studies, little is known about which function is essential, or if multiple pathways are required, for p53-dependent tumor suppression in vivo. Using a mouse brain carcinoma model that shows high selective pressure for p53 inactivation, we found that even partially abolishing p53-dependent apoptosis by Bax inactivation was sufficient to significantly reduce the selective pressure for p53 loss. This finding is consistent with previous reports that apoptosis is the primary p53 function selected against during Em-myc-induced mouse lymphoma progression. However, unlike observed in the Em-myc-induced lymphoma model, attenuation of apoptosis is not sufficient to phenocopy the aggressive tumor progression associated with complete loss of p53 activity. We conclude that apoptosis is the primary tumor suppressive p53 function and the ablation of additional p53 pleiotropic effects further exacerbates tumor progression. Mol Cancer Res; 9(4); 430-9. Ó2011 AACR.
Introduction
p53 is frequently mutated in a wide array of human cancers (1, 2) . A variety of cell stresses, such as DNA damage, hypoxia, or cell-cycle aberrations, evoke a p53 transcriptional response, which modulates multiple physiologic pathways including cell-cycle arrest, apoptosis, genome surveillance, senescence, and angiogenesis (3) (4) (5) (6) (7) . The pleiotropic effects of p53 make it difficult to distinguish whether a single p53-dependent function is uniquely responsible for the active selection against p53 activity during tumorigenesis, or if selective pressure is directed against the p53's aggregate activities, since loss of any one or combination of these functions could account for the prevalence of p53 mutations among human cancers.
Several investigators (8) (9) (10) (11) have attempted to dissect the functions of p53 in vivo using the Em-myc transgenic mouse model of B-cell lymphoma (12) in which the immunoglobulin heavy chain enhancer drives expression of c-myc. In these lymphomas, apoptosis is the essential p53-dependent function suppressing tumor progression (9, 10) . Reduced activity of Bax, a downstream effector of p53-mediated apoptosis, circumvented p53 mutations usually acquired during progression (9) . Further evidence for the importance of apoptosis on the selective pressure against p53 is the reduced frequency of p53 LOH in lymphomas that harbor a single p53 null allele (Em-myc;p53 þ/À ; ref. 10) . Overexpressing either the Bcl2 gene or a dominantnegative form of caspase 9 blocks apoptosis and dramatically reduces p53 LOH. Moreover, lymphomas in which apoptosis is completely abolished acquire an aggressive Em-myc phenotype, despite retention of the wild-type p53 allele, indicating that reduced apoptosis not only reduces selective pressure against p53, but is also sufficient for lymphoma progression.
Whether apoptosis is the essential p53-dependent tumor suppressive function in epithelium-derived carcinomas has not been studied in vivo. Here, we investigated the selective pressure against p53 activity using a brain cancer model we previously described (13) . In this model, we directed expression of a truncated SV40 T antigen (T 121 ) in the mouse choroid plexus epithelium (CPE) and evaluated the effects of p53 loss on tumor progression. The CPE lines the ventricles of the mammalian brain, forming the blood-brain barrier and produces cerebral spinal fluid. Normally, CPE cells cease dividing within 2 weeks of birth. The T 121 oncoprotein specifically inactivates pRb-related pocket proteins (pRb, p107, and p130), which causes cell-cycle re-entry. The unscheduled proliferation triggers apoptosis or predisposes cells to dysplastic growth followed by progression to carcinoma (13, 14) .
p53 plays a significant role in suppressing tumorigenesis in transgenic (Tg) T 121 mice. Removing p53 activity greatly reduces the apoptosis elicited by T 121 expression in this brain tumor setting, with approximately half the apoptosis mediated by the p53 effector gene, Bax (14, 15 þ/þ mice that inactivate p53 were highly angiogenic, yet tumors lacking p53 activity displayed little or no aneuploidy (16) , contrary to the widely held view that p53 is largely responsible for surveying genomic integrity.
The correlation between accelerated tumor progression and decreased apoptosis suggests a critical role for apoptosis in executing tumor suppression by p53 in our brain tumor model. However, other p53-mediated functions, such as angiogenesis inhibition (Yin and colleagues, unpublished results), or senescence may also subject the cell to selective pressure for p53 loss. In the present study, we explored the significance of p53-dependent apoptosis in CPE tumor suppression. We hypothesized lower apoptosis levels should decrease selective pressure for p53 loss. We show reducing Bax-mediated apoptosis does indeed prevent the loss of p53 activity; whereas, deficiency of an alternative p53 effector not involved in apoptosis, p21, does not alleviate selective pressure against p53. Loss of p53-dependent apoptosis, however, is not sufficient for progression to the more aggressive brain tumor phenotype associated with the complete absence of p53 activity. The subsequent loss of pleiotropic p53 functions allows tumors to acquire additional, distinct tumor phenotypes. Although the influence of p53 effectors is likely cell typeand condition-specific, apoptosis serves as the primary p53 function that is actively selected against during tumor progression in both our brain carcinoma model and the Em-myc lymphoma model.
Materials and Methods

Mice
TgT 121 transgenic mice (C57BL6/J; DBA2, F1 hybrid background) were previously described (13, 14, 17) . Bax
À/À (C57BL6/J), and p21 À/À (C57BL6/ 129 hybrid) mice have been described (18) (19) (20) 
Histology
Mouse brains were fixed in 10% formalin, embedded in paraffin, and cut in 5-mm sections. To examine tumor morphology, brains were sectioned for 6 to 10 consecutive layers with a 50-mm interval between each layer and then 5-mm sections from each layer were stained with hematoxylin and eosin (H&E).
RNA in situ hybridization
Sections were treated and hybridized as previously described (16) . The p21 antisense probe was generated by T7 transcription of an EcoRI-linearized pBS-KSp21 template. The Bax antisense probe was generated by T3 transcription of an ApaI-linearized pBS-SKpBax template. Probes were labeled with [g-35S] UTP (5 Â 10 4 cpm/mL) and hybridized to slides at 50 C overnight. Slides were exposed for 3 days (p21) or 8 weeks (Bax).
p53 immunohistochemistry
Paraffin-embedded sections were boiled in Trilogy buffer (Cell Marker) for 15 minutes and then cooled at room temperature for 30 minutes. Sections were blocked in 10% normal goat serum (NGS) in PBS for 1 hour at room temperature. Sections were incubated with rabbit antimouse p53 polyclonal antibody (Novocastra Laboratories Ltd.) at 1:600 dilution in 10% NGS at 4 C overnight. The secondary antibody staining and peroxidase enzymatic reactions were performed using an ELITE kit (Vector Laboratories Inc.). After applying the DAB (3,3 0 -diaminobenzidine) substrate, sections were incubated for 3 to 6 minutes and the staining was monitored by microscopy. Slides were counterstained with methyl green.
Statistical analysis
Fisher's exact test was used to evaluate the significance of differences in p53 inactivation frequencies between tumors derived from alternative genotypes. P values less than 0.05 were deemed significant.
Results
To assess whether apoptosis is the essential p53 tumor suppressor function selected against during brain tumor progression, we examined the frequency of p53 inactivation in TgT 121 mice with Bax deficiency. Bax mediates nearly half of apoptosis in this brain tumor model (15) ; although, Bax deficiency alone, without TgT 121 , does not cause abnormal proliferation or tumorigenesis in CPE. We assessed p53 activity in 2 ways, first, we evaluated the histology of TgT 121 CPE tumors as an indicator of the tumor's p53 status, as we have previously determined that p53 activity directly correlates with tumor histology in this model (16) . Second, we assayed gene expression levels of the p53 target gene, p21 (21) . A functional assessment of p53 status is important since diverse mutations could render p53 inactive. Importantly, we have shown that p21 transcription depends on p53 activity and p21 does not play a direct role in p53-dependent apoptosis in this brain carcinoma model (16, 17, 22) .
TgT 121 mice develop tumors with 2 distinct morphologies that we designated as type I and type II tumors (Table 1) , which we previously have shown correspond to p53 functional status (16) : type I tumors invariably show loss of p53 function (100%, n ¼ 34 tumors), whereas type II tumors retain p53 function. Type I tumors have greater tumor volume and higher cell density with abundant blood vessels and perivascular polarity, whereas type II tumors show a dysplastic morphology and pleomorphic nuclei, with overall smaller tumor volume and fewer blood vessels. Type I tumors are more rare than type II tumors in TgT 121 mice (38% vs. 62%, respectively), presumably because the type I phenotype requires loss of both active p53 alleles.
To test the effect of reducing Bax-mediated apoptosis on brain tumor histology, we generated TgT 121 mice that differed with respect to their Bax genotype (
. We confirmed that the histologic characteristics of tumors derived from TgT 121 ;Bax þ/þ sibling mice were consistent with our previous observations of TgT 121 mice, for both the type I ( Fig. 1A and C) and type II (Fig. 1B and D) tumors, despite the mixed genetic backgrounds generated by intercrossing the 2 mouse strains. Importantly, the mixed genetic background in the present study had little effect on the tumor spectrum we previously reported. The (Fig. 1E) . Consistent with our hypothesis, when apoptosis was reduced through lower Bax levels, fewer tumors displayed the type I phenotype that is associated with complete loss of p53 function.
To confirm our histologic assessment of p53 activity, we assayed p21 expression levels as a second indicator of p53 function, since p21 expression depends on p53 in this system (Fig. 2) . The p21 sense probes did not show signal above background (data not shown). These results are summarized in Figure 3A . Taken together, our analysis of tumor histology and p21 gene expression Figure 3 . Bax deficiency decreases the frequency of p53 inactivation, associated with type I tumor histology. A, Bax deficiency reduces the frequency of type I tumors. Some of the type I and type II tumors were analyzed by p21 RNA in situ hybridization to confirm p53 status as shown in Figure 2B . , survival curves of mice with different genotypes as analyzed in (A). C, Bax deficiency decreases selective pressure for p53 inactivation in TgT 121 tumors that harbor a single p53 allele. The vast majority of tumors derived from Bax null mice are type II tumors (p53 active), indicating p53 loss is greatly decreased. In contrast, p21 nullizygous mice, which show a similar life span and incidence of hydrocephaly as Bax nullizygous mice, still retain high p53 inactivation rates, indicating the effect is Bax specific. Some of the tumors were analyzed by p21 RNA in situ hybridization as shown in Figure 4D . survival curves of mice with different genotypes analyzed in (C). Fisher's exact test was used to compare tumor type distribution differences between different groups; **, P < 005. indicate that although Bax mediates only half of p53-dependent apoptosis in our brain tumor model, reduced Bax activity greatly reduces the frequency of p53 inactivation. Next, we assayed the frequency of p53 inactivation in tumors of mice that harbored a single engineered mutant p53 allele. The rationale for these experiments was 2-fold: first, with only a single p53 allele, tumors would be more susceptible to complete loss of p53 function, thus making a more sensitive assessment of p53 activity levels. Indeed, 100% of tumors derived from TgT 121 ;p53 þ/À mice progress to the type I phenotype and virtually all (94%) lose the active p53 allele (17) . Our second rationale was based on our observation that the majority of TgT 121 ;Bax À/À mice (12/ 14) developed severe hydrocephaly (Fig. 1F) Fig. 3A  and B) . The shortened time frame among the TgT 121 ; Bax À/À mice might be insufficient to allow tumor cells to lose both p53 alleles and display the type I tumor phenotype; although, we know that type I CPE tumors can develop in TgT 121 mice as early as 8 to 9 weeks (ref. 16 and Lu, unpublished data).
We generated both TgT 121 ;Bax þ/À ;p53 þ/À and TgT 121 ; Bax À/À ;p53 þ/À mice and, as above, characterized p53 inactivation by evaluating tumor histology (Fig. 4A and C) and p21 expression (Fig. 4B and D) . Bax heterozygosity (TgT 121 ;Bax þ/À ;p53 þ/À , only modestly reduced the incidence of Type I tumors we previously observed among mice wild type for Bax (i.e., TgT 121 ;p53 þ/À ; 87% vs. 100%, respectively; Fig. 3C ). In stark contrast, and consistent with our prediction, the incidence of type I tumors (20%) was greatly reduced among Bax nullizygous mice (TgT 121 ; Bax À/À ;p53 þ/À ; Fig. 3C ). Moreover, the lower frequencies of type I tumors observed in animals with reduced Bax activity (TgT 121 ;Bax þ/À ;p53
and TgT 121 ;Bax À/À ; p53
) indicates a bona fide shift in tumor spectrum and not an artifact caused by the comorbidity of hydrocephaly, since TgT 121 ;p53 þ/À mice develop type I tumors with a latency (t 50 ¼ 9 weeks) within the expected life span of Bax null mice ( Fig. 3C and D; ref. 16 ). Furthermore, p21 expression directly correlates with differences in tumor morphology, as we have shown previously (16) and therefore serves as an indicator of p53 functional status (Fig. 4) . Taken together, these results are consistent with a model in which reduced Bax-mediated apoptosis alleviates selective pressure against p53 even in the context of tumors sensitized to p53 loss.
As an additional control for these experiments, we also assessed the effects of loss of p21, a p53 downstream cellcycle arrest gene, on selective pressure against p53 activity. We reasoned if selective pressure is working primarily against p53 apoptotic activity, then the incidence of type I tumors should remain high even when we mutate a p53 effector that is not involved in apoptosis. p21-deficient mice are more prone to tumorigenesis in multiple tissues at old age (24) . However, p21 does not contribute to p53-induced apoptosis in the TgT 121 brain tumor model in the absence of DNA damage (22) . We generated a cohort of TgT 121 ;p21 À/À ;p53 þ/À mice, then used p53 immunostaining to evaluate p53 status in their tumors (Fig. 5E-H) . Among the tumors examined (n ¼ 17), 76% were type I tumors, 18% were type II tumors, and a single mouse developed both tumor types (Fig. 4C) . Since the type I tumor frequency is significantly higher than we observed in TgT 121 ;Bax À/À ;p53 þ/À mice (82% vs. 20%; P < 0.05), we conclude that selection against p53 remains high despite the absence of p21 function. These results are consistent with a model where a p53-dependent function, which is not mediated by p21, is actively selected against during brain carcinoma progression. Furthermore, because p21 deficiency also causes hydrocephaly to a similar extent as Bax deficiency in TgT 121 and TgT 121 ;p53 þ/À mice (data not shown), it also helps to rule out the possibility that hydrocephaly directly affects the selective pressure against p53 during CPE tumor progression.
Given the importance of Bax in p53-dependent apoptosis in CPE and our observation that Bax deficiency reduced the selective pressure against p53 during CPE tumor progression, we reasoned that the Bax gene itself might also be subject to selective pressure. Among human cancers, reduced Bax expression is associated with poor clinical outcome in ovarian cancer (25) , metastatic breast adenocarcinoma (26) , and squamous cell carcinoma (27) . Bax frameshift mutations have also been observed in colorectal cancers (28) . We tested this hypothesis using in situ hybridization to determine Bax gene status in
No tumors showed loss of Bax expression (Fig. 5) . Negative control Bax sense probes did not show signal above background (data not shown). Although this assay cannot rule out Bax loss of function caused by frameshift or missense mutation, we suspect Bax is not subject to high selective pressure in this tumor setting. This result is perhaps not surprising, since Bax mediates only 50% of p53-dependent apoptosis in our brain tumor model, and losing additional pleiotropic p53 effects would confer greater advantage to tumors than Bax loss alone.
Discussion
The p53 tumor suppressor plays important roles in cellcycle control, apoptosis, senescence, DNA repair, genomic stability maintenance, and regulation of angiogenesis. Together, these diverse functions contribute to p53's tumor suppressive activity. Until recently, little was known about which p53 function is essential for tumor suppression in vivo and therefore actively selected against during tumor progression. During lymphomagenesis, apoptosis appears to be the primary p53 function selected against, since selective pressure for p53 loss was alleviated by reduced apoptosis levels (8) (9) (10) . Because the roles of p53 effectors are likely cell-and condition-specific, it is unclear whether apoptosis is also the essential target for selection during carcinoma progression.
To address this issue, we used the well-characterized brain carcinoma model in which CPE tumors are induced by expression of a T antigen mutant, T 121 , transgene in CPE cells (14) . An advantage of the TgT 121 model is the immense selective pressure against p53 activity during CPE tumor progression. The frequencies of p53 inactivation during TgT 121 or TgT 121 ;p53 þ/À tumor progression were 38% and 100%, respectively (16) . To test the contribution of p53-dependent apoptosis to brain carcinoma suppression, we reduced p53-dependent apoptosis by inactivating a single downstream apoptotic gene, Bax. The absence of Bax activity (TgT 121 ;Bax À/À ) completely suppressed the inactivation of p53, compared with the one third of tumors derived from TgT 121 ;Bax þ/þ mice that showed p53 inactivation. These results are consistent with our hypothesis that the reduced level of Baxmediated apoptosis alleviates the selective pressure against p53 (Fig. 6) .
A potential confounding factor in our experiments was the shortened life span of TgT 121 ;Bax À/À mice compared with TgT 121 ;Bax þ/þ mice (9 vs. 32 weeks) that likely results from the combination of rapid tumor progression and high incidence of severe hydrocephaly. A shorter time frame might be insufficient to lose both p53 alleles required to reveal the type I phenotype. To avoid this potential problem, we analyzed tumor progression in mice harboring a single p53 null allele (TgT 121 ;Bax þ/þ mice (16) . Even in the sensitized background of p53 heterozygosity, the absence of Bax activity significantly reduced selective pressure against p53. To further exclude the possibility that severe hydrocephaly directly affected selective pressure against p53, we also analyzed TgT 121 ;p21 À/À ;p53 þ/À mice, which have survival times similar to TgT 121 ;Bax À/À ;p53 þ/À mice, and also develop severe hydrocephaly. The selective pressure against p53, evidenced by the high incidence of type I tumors, was not diminished by the p21 null background. We conclude a shorter life span associated with hydrocephaly does not preclude the type I tumor phenotype. Instead, Baxmediated apoptosis rather than p21 function is the target of selective pressure in tumors derived from brain epithelial cells.
Our studies also revealed notable distinctions between the brain carcinoma and B-cell lymphoma models. In the lymphoma model, Bcl-2 overexpressing tumors advance to a phenotype that is morphologically indistinguishable from p53-deficient tumors, indicating that apoptosis alone is sufficient for tumor progression (10), even though others have shown nonapoptotic p53 functions also contribute to lymphoma tumor suppression (11, 29, 30) . In contrast, in the brain carcinoma model, p53 status corresponds to distinctive tumor biology and behavior. Tumors that completely lose p53 activity (type I) show tumor phenotypes associated with more aggressive and malignant tumors; whereas, tumors that maintain p53 activity (type II), despite the absence of Bax activity, show a comparatively less aggressive phenotype (Table 1) . Therefore, p53-dependent pathways other than Bax-mediated apoptosis determine the advancement to malignancy unlike the lymphoma model (Fig. 6 ). Other studies from our laboratory also point to the importance of losing p53 functions other than apoptosis during tumor progression. We have also characterized tumors derived from TgT 121 mice harboring p21 and/or gadd45 null alleles. Only p53 inactivation, but not loss of Bax, p21, gadd45 (or p21 and gadd45 combined), leads to aggressive brain carcinoma (type I tumors). p53 also appears to play a significant role in angiogenesis inhibition among CPE carcinomas, which we are currently characterizing (Yin and colleagues, unpublished results). Taken together, these observations support our interpretation that the selective pressure for p53 inactivation is due primarily to its role in apoptosis, whereas inactivating other p53-mediated functions contributes to further tumor progression.
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